Effect of Olivomed (Olive Extract) on Endothelial, Cardiac and Vascular Function of Patients With Stable Coronary Artery Disease
Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Olive extracts are considered to have antioxidant properties. The investigators will study the effect of olive extracts containing hydroxytyrosol (HT)-olivomed and combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - olivomedSmart on endothelial, cardiac and vascular function in patients with coronary artery disease .
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Age \<70 years
• Stable coronary heart disease
• Patients with acute coronary syndrome who have undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), 2 months must have passed since the incident
• High LDL levels, low HDL, high triglycerides
Locations
Other Locations
Greece
Attikon University General Hospital
RECRUITING
Athens
Contact Information
Primary
Ignatios Ikonomidis
ignoik@gmail.com
+302105832187
Backup
Konstantinos Katogiannis
kenndj89@gmail.com
+306938165687
Time Frame
Start Date: 2020-12-01
Estimated Completion Date: 2026-08-01
Participants
Target number of participants: 30
Treatments
Active_comparator: olive extract 1 - olivomed
15 patients will be randomized to receive two Olivomed soft capsules bid for one month (5 mg hydroxytyrosol po twice daily) and then they will be crossed over to treatment placebo for another one month.
Placebo_comparator: placebo 1
15 patients will be randomized to receive two placebo soft capsules bid for one month. Then they will be crossed over to receive two Olivomed soft capsules bid for oen month (5 mg hydroxytyrosol po twice daily)
Active_comparator: olive extract 2 - olivomedSmart
15 patients will be randomized to receive two soft capsules containing OL:HT:OC (2:1:3) bid for one month (5 mg hydroxytyrosol po twice daily) and then they will be crossed over to treatment placebo for another one month.
Placebo_comparator: placebo2
15 patients will be randomized to receive two placebo soft capsules bid for one month. Then they will be crossed over to receive two soft capsules containing OL:HT:OC (2:1:3) bid for one month (5 mg hydroxytyrosol po twice daily) bid for one month.
Related Therapeutic Areas
Sponsors
Leads: University of Athens